Non Estrogen Oral Therapy

SUPPLEMENT TO OBG MANAGEMENT 

Ospemifene, An Oral SERM for Dyspareunia of Menopause: Is it Being Underutilized?

Vulvovaginal Atrophy:An Undertreated Disorder

Learning Objectives
  1. Understand the pathophysiology of dyspareunia due to vulvovaginal atrophy (VVA) of menopause.
  2. Appreciate the underrecognition and undertreatment of dyspareunia due to VVA. 
  3. Discuss efficacy results of randomized placebo controlled trials of ospemifene. 
  4. Understand the adverse events associated with ospemifene. 
  5. Appreciate the safety data of ospemifine as well as other oral selective estrogen receptor modulators and estrogens. 

 

Date of Original Release: February 1, 2019
Date Credits Expire: January 31, 2022

Faculty
Program Director
Steven R. Goldstein, MD, CCD, NCMP, FACOG
Professor of Obstetrics and Gynecology
New York University School of Medicine
Director of Gynecological Ultrasound
Co-Director of Bone Densitometry and Body Composition
Department of Obstetrics and Gynecology
New York University Medical Center
New York, New York
Author
James A. Simon, MD, CCD, NCMP, IF, FACOG
Clinical Professor
George Washington University School of Medicine
President and Medical Director
Women’s Health & Research Consultants®
Washington, District of Columbia

World Class CME designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity is supported by an unrestricted educational grant from Duchesnay.

CME credit may only be awarded to physicians. 

World Class CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Take The Survey and Quiz

Our live World Class CME conferences for 2022 are open for registrations! In addition we offer monthly webinars in breast imaging and have other online course options.